Renalvita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 188,489 | 223,390 | 282,559 | 321,388 | 320,077 | 443,838 | 551,798 | 545,791 |
| Profit before tax | 5,681 | 39,975 | 51,997 | 76,636 | 25,187 | 103,178 | 147,745 | 131,270 |
| Net profit | 5,681 | 39,975 | 51,997 | 76,636 | 25,187 | 102,800 | 147,745 | 110,267 |
| Equity | 8,934 | 48,909 | 100,906 | 79,889 | 48,440 | 151,240 | 150,931 | 113,453 |
| Liabilities | 94,629 | 47,330 | 25,025 | 30,661 | 87,686 | 27,558 | 34,286 | 49,645 |
| Non-current assets | 45,715 | 36,239 | 45,790 | 47,844 | 70,609 | 82,331 | 59,293 | 33,390 |
| Current assets | 57,294 | 59,404 | 79,840 | 62,401 | 65,119 | 96,068 | 125,438 | 129,205 |
| Total assets | 103,009 | 95,643 | 125,630 | 110,245 | 135,728 | 178,399 | 184,731 | 162,595 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 47,515 | 70,659 | 74,362 |
| Social insurance contributions | - | - | - | - | - | 46,648 | 56,558 | 59,832 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -7.6% | +18.5% | +26.5% | +13.7% | -0.4% | +38.7% | +24.3% | -1.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.5% | 41.8% | 41.4% | 69.5% | 18.6% | 57.6% | 80.0% | 67.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 63.6% | 81.7% | 51.5% | 95.9% | 52.0% | 68.0% | 97.9% | 97.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.0% | 17.9% | 18.4% | 23.8% | 7.9% | 23.2% | 26.8% | 20.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.0% | 17.9% | 18.4% | 23.8% | 7.9% | 23.2% | 26.8% | 24.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 10.6 | 1.0 | 0.2 | 0.4 | 1.8 | 0.2 | 0.2 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,366 | 16,346 | 19,945 | 21,426 | 19,799 | 25,362 | 29,429 | 33,935 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Renalvita - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-09-17 | 2024-09-22 | 0.38 |
| 2024-08-19 | 2024-09-05 | 0.40 |
| 2024-07-24 | 2024-08-04 | 0.40 |
| 2024-06-18 | 2024-06-19 | 566.93 |
| 2022-12-16 | 2023-01-05 | 1.49 |
| 2021-11-16 | 2021-11-17 | 4.34 |
Renalvita - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Renalvita, UAB (code 184265443) is a Private Limited Liability Company engaged in diagnostic imaging services and medical laboratory activities. In the latest financial year, 2025, the company generated revenue of €545.8K and net profit of €110.3K, which corresponds to a profit margin of 20.2%. Revenue decreased slightly by 1.1% year on year, but remained 23.0% above the 2023 level. The multi-year trend shows growth from €443.8K in 2023 to €551.8K in 2024, followed by a small decline in 2025, while profit peaked in 2024 at €147.7K before easing in 2025. At the end of 2025, total assets stood at €162.6K, equity at €113.5K and liabilities at €49.6K. The balance sheet indicates a solid equity position, with an equity ratio of 69.8% and debt-to-equity of 0.44. Asset turnover was 3.36x, ROE 97.2% and ROA 67.8%. Revenue per employee was €34.1K and profit per employee €6.9K.